Management of neuroblastoma in limited-resource settings by Van Heerden, Jaques & Kruger, Mariana
WJCO https://www.wjgnet.com 0 August 24, 2020 Volume 11 Issue 8
World Journal of 
Clinical OncologyW J C O
Submit a Manuscript: https://www.f6publishing.com World J Clin Oncol 2020 August 24; 11(8): 0-0
DOI: 10.5306/wjco.v11.i8.0000 ISSN 2218-4333 (online)
REVIEW
Management of neuroblastoma in limited-resource settings
Jaques van Heerden, Mariana Kruger
ORCID number: Jaques van Heerden 
0000-0002-4502-1169; Mariana 
Kruger 0000-0002-6838-0180.
Author contributions: van Heerden 
J conceptualised and designed the 
study, sourced and screened 
articles, collected the data and 
performed the data analysis and 
wrote the manuscript; Kruger M 
conceptualised and designed the 
study, evaluated the source articles 
and critically reviewed and edited 
the manuscript.
Conflict-of-interest statement: All 
the authors declare that they have 
no competing interests.
PRISMA 2009 Checklist statement: 
The guidelines of the PRISMA 2009 
Statement have not been adopted, 
because the review is a descriptive 
review.
Open-Access: This article is an 
open-access article that was 
selected by an in-house editor and 
fully peer-reviewed by external 
reviewers. It is distributed in 
accordance with the Creative 
Commons Attribution 
NonCommercial (CC BY-NC 4.0) 
license, which permits others to 
distribute, remix, adapt, build 
upon this work non-commercially, 
and license their derivative works 
on different terms, provided the 
original work is properly cited and 
the use is non-commercial. See: htt
p://creativecommons.org/licenses
/by-nc/4.0/
Jaques van Heerden, Mariana Kruger, Department of Paediatrics and Child Health, Faculty of 
Medicine and Health Sciences, Stellenbosch University, Cape Town 8000, South Africa
Jaques van Heerden, Department of Paediatric Haematology and Oncology, Antwerp University 
Hospital, Edegem 2650, Belgium
Corresponding author: Jaques van Heerden, MD, Doctor, Department of Paediatric 




Neuroblastoma (NB) is a heterogeneous disease with variable outcomes among 
countries. Little is known about NB in low- and middle-income countries 
(LMICs).
AIM 
The aim of this review was to evaluate regional management protocols and 
challenges in treating NB in paediatric oncology units in LMICs compared to 
high-income countries (HICs).
METHODS 
PubMed, Global Health, Embase, SciELO, African Index Medicus and Google 
Scholar were searched for publications with keywords pertaining to NB, LMICs 
and outcomes. Only English language manuscripts and abstracts were included. 
A descriptive review was done, and tables illustrating the findings were 
constructed.
RESULTS 
Limited information beyond single-institution experiences regarding NB 
outcomes in LMICs was available. The disease characteristics varied among 
countries for the following variables: sex, age at presentation, MYCN 
amplification, stage and outcome. LMICs were found to be burdened with a 
higher percentage of stage 4 and high-risk NB compared to HICs. Implementation 
of evidence-based treatment protocols was still a barrier to care. Many 
socioeconomic variables also influenced the diagnosis, management and follow-
up of patients with NB.
CONCLUSION 
Patients presented at a later age with more advanced disease in LMICs. 
Management was limited by the lack of resources and genetic studies for 
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improved NB classification. Further research is needed to develop modified 
diagnostic and treatment protocols for LMICs in the face of limited resources.
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Core tip: Neuroblastoma (NB) is a childhood malignancy of the sympathetic system that 
accounts for a large percentage of the childhood malignancy mortality. The heterogenous 
presentation contributes to various treatment challenges especially in low- and middle-
income countries (LMICs). NB in LMICs has not been investigated beyond single 
institutions, but the limited reports differ from those in high-income countries (HICs). The 
incidence of NB in LMICs has been reported to be lower than HICs, but the disease 
presents with a higher incidence of high-risk and advanced disease. Furthermore, the 
limited resources in these countries contribute to the challenges in the management of NB 
that leads to a high mortality rate. The genetic profile of NB in LMICs is also not known 
due to limited capacity to perform genetic investigations. This article aims to 
comprehensively describe NB in LMICs.
Citation: van Heerden J, Kruger M. Management of neuroblastoma in limited-resource settings. 




The burden of disease in low- and middle-income countries (LMICs) is predominantly 
infectious in origin[1,2]. Yet, it is shifting towards non-communicable diseases such as 
congenital diseases, malignancies and road traffic incidents[2,3]. To date, the focus in 
research has been on communicable paediatric diseases with the World Health 
Organization’s initial integrated management of childhood illness programme being 
one example[2]. Building the capacity of health care professionals to identify childhood 
malignancies has not been optimal[4]. This possibly explains the 28%-49% childhood 
malignancy gap reported between LMICs and high-income countries (HICs)[5].
Neuroblastoma (NB) data from HICs are well documented, whereas data from 
LMICs are limited. NB, predominantly a childhood malignancy, remains a major 
contributor to childhood cancer mortality and accounts for up to 15% of paediatric 
malignancy-related deaths[6]. Even with increased-intensity treatment in HICs, the five-
year overall survival (OS) remains approximately 60%[7]. However, there is a major 
divide between HICs and LMICs due to the advances in diagnostics, treatment options 
and outcomes of NB in HICs[8].
Because of the variability of NB symptoms, they can easily be misdiagnosed as 
infections, bone marrow failure, neuropathology and obstructive enteropathies in 
LMICs by primary health care workers. Nurse-led primary care clinics or general 
practitioners may not have the expertise to recognise rare diseases in children and are 
often the first contact versus HICs where the first contact is usually more experienced 
health care workers[9].
Early diagnosis is crucial and necessitates a high index of suspicion with 
appropriate risk stratification and treatment[5]. The prognosis of NB is determined by a 
set of well-described prognostic factors that include patient factors (age at diagnosis), 
biochemical factors (lactate dehydrogenase and ferritin), tumour-related factors 
(primary site, tumour histology and stage), biological factors (MYCN amplification, 
ploidy and loss of chromosome 1p) and management factors (post-induction 
metastatic remission and degree of resection)[10,11]. NB pathophysiology and biological 
features, predominantly MYCN status, loss of chromosome 1p and ploidy, determine 
the spontaneous regression or aggressive growth and spread of metastases but do not 
explain the international difference in characteristics completely[6]. Similarly, notable 
differences in outcomes have been reported for risk classifications between LMICs and 
HICs with similar therapies[12-16]. The aim of this narrative review was to evaluate 
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regional variations in the diagnosis and management of NB in LMICs versus HICs.
MATERIALS AND METHODS
A comprehensive literature review of publications on PubMed, Global Health, 
Embase, SciELO, African Index Medicus and Google Scholar with medical subject 
headings pertaining to NB and outcomes relating to LMICs was done. Search terms 
included (but were not limited to) ‘neuroblastoma’, ‘limited resources’, ‘low-income’, 
‘middle-income’ and names of LMICs. The search was conducted from April 2019 to 
January 2020 with terms adapted according to search engines without limitations on 
the date or language, provided that English summaries or abstracts were included. 
Conference proceedings were included. No authors were contacted regarding 
publications.
Due to the variability in reporting, nonstandard application of definitions in the 
reported clinical results, heterogeneous data and paucity of information, the authors 
constructed limited tables to evaluate clinical and/or biological characteristics to 
report in the descriptive review.
The systemic literature search retrieved 127 articles, abstracts and documents on NB 
in LMICs. After removing 11 documents for possible duplicated reporting, the 116 
remaining documents consisted of 13 cancer registry-based reports and 103 non-
registry-based documents. Twenty-three non-registry-based, nonrandomised studies 
(two prospective studies and 21 retrospective studies) were selected. All 116 articles, 
including the remaining 83 articles that were not specific to NB but contained 
epidemiological and non-interventional data on NB, were utilised to draw descriptive 
conclusions regarding epidemiological elements and outcomes for NB in the 
respective countries. Despite significant population numbers, certain LMIC regions 
were underrepresented in this review due to possible publication bias of reports.
RESULTS
Data from Asia (China, India, Pakistan, Thailand and Vietnam)[13,17-22], the Middle East 
and North Africa (Egypt, Iran, Iraq and Morocco)[23-28] and the Americas (Argentina, 
Brazil, Chile, Cuba, Mexico and Uruguay)[12,16,29-35] were accessible, but reports from 
sub-Saharan Africa and the Pacific Ocean were limited to single reports from the 
French-African Paediatric Oncology Group (GFAOP) and reunion[15,36]. The differences 
between HICs and LMICs could be evaluated from these reports, but complete 
management and outcome data for interregional variations among LMIC regions were 
less robust.
Incidence of neuroblastoma in low- and middle-income countries versus high-
income countries according to international cancer registries
In sub-Saharan Africa, the incidence of NB was low, ranging from 0.4 cases per million 
in Niger to 5.9 cases per million in Kenya[37], compared to HICs such as North America 
and Europe where the respective incidences were reported as 10.5 and 11.6 cases per 
million per year in children younger than 15 years [11,38,39]. South Africa reported an 
incidence of 2.68 cases per million in children under 15 years of age between 1985 and 
2007[40]. In Argentina, intraregional variations in incidence were demonstrated with a 
higher incidence being associated with areas of high socioeconomic status[29]. Yet, the 
international incidences have remained stable regardless of economic status[41]. As 
perinatal and low-risk (LR) NB can be asymptomatic and/or spontaneously regress, 
underdiagnosis of cases is a possible reason[5,37] but the degree of discrepancy is not 
known.
Epidemiology of neuroblastoma in low- and middle-income countries
Difference in age at presentation: In LMICs, the majority of patients were under the 
age of 5 years, but the percentages of infants reported for China (16.3%) and India 
(5.9%) (Table 1) were low. The mean or median age of presentation was delayed in 
some LMICs. In Thailand, the median was 34.8 mo of age and in India as high as 48 
mo of age. The median age of presentation in the 16 paediatric oncology units (POUs) 
of the GFAOP study was 48 mo as well[15]. The age-standardised rates varied among 
countries, but the ratio of patients under 12 to 60 mo could be as low as 2.3:1 in 
Argentina and 1.2: 1 in Brazil compared to an HIC like Germany with a 4:1 ratio 
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Table 1 Age distribution at diagnosis
Country n < 12 mo < 18 mo < 60 mo < 120 mo < 180 mo Mean Median
Asia
China (2008-2013)[17] 59 44% 56% 24
China (2000-2006)[18] 98 16.3% 4.1% 53% 21.5% 4% 48
India (1990-2004)[19] 103 0%-5.9% 77%-98.1% 1.9% 41 -
Pakistan (2015-2016)[20] 70 30% 63% 7% 36
South America
Argentina (2000-2012)[29] 753 30% 52.2% 12.9% 45.3% 26.4
Brazil (1991-2012)[30] 258 29% 49% 17% 5% 40.5 28.9
Brazil (1990-2000)[16] 125 26% 13% 41% 20% 38.2 33
Middle East and North Africa
Egypt (2005-2010)[23] 142 24.2% 75.8% 30
Egypt (2001-2010)[24] 53 22.6% 77.4%
Iran (1974-2005)[25] 219 21.5% 78.5% 40.5
Iraq (2008-2014)[26] 62 30.6% 50% 16.1% 3.2% 37
Sub-Saharan Africa
Ethiopia (2010-2013)[79] 5 0 40% 40% 20%
Kenya (1997-2005)[44] 22 31.8% 50% 18.2% 60
(Table 2). However, other LMICs such as Cuba (4.8:1), with a good reputation for 
health care, and Reunion (2.7:1), a French territory in Africa, compared favourably 
with the United States of America (2.4:1) in this regard (Table 1). The median age of 
presentation in HICs was reported to be between 17 and 18 mo of age, of whom 
approximately 40% were diagnosed under 1 year of age[41]. Many studies have 
reproduced the 18-mo watershed dividing good prognosis (under the age of 18 mo) 
and poorer prognosis (over the age of 18 mo). Stage 4 patients were per definition 
below 12 mo of age with a good prognosis. In HICs, 90% of NB patients were younger 
than 5 years at diagnosis, with a median age at diagnosis of 19 mo, and 37% of patients 
had been diagnosed as infants[11]. The ATRX-gene is associated with advanced-age 
presentations, especially over 9 years of age, conferring a poorer prognosis in 
adolescents and adults[42]. The paucity of genetic studies in LMICs limited the 
interpretation of gene mutations related to age at diagnosis.
Gender distribution at diagnosis: The GFAOP reported that the male to female ratio 
for 16 African POUs was 2: 1[15]. In other LMICs, the male predominance as well as the 
greater male to female ratio was reproducible (Table 3). The ratios varied from 1.06: 1 
to 2: 1. Previous studies from Southern Africa reported a ratio of 1.7:1[43] in keeping 
with the male predominance, while a Mexican study reported a lower NB incidence of 
2.5-4.1 cases per million per year, in keeping with the situation in other LMICs, yet the 
male to female ratio of 1.1:1 was similar to HICs[32]. Kenya also reported a 1: 1 ratio in 
an LMIC setting[44]. The incidences based on gender have not been explained by other 
biological features. These findings were in contrast to the reported surveillance, 
epidemiology, and end results programme data from North America and European 
data, according to which a slight male predominance with a ratio of 1.1:1 was 
noted[38,45].
Population variations: Population variations related to epidemiology and 
pathophysiology contributed to a difference in the presentation of high-risk (HR) 
disease but not non-HR disease[46]. Independent from social circumstances, certain 
ethnicities were diagnosed at an older median age (> 20 mo) and had a higher 
prevalence of stage 4 disease and unfavourable histology tumours (undifferentiated 
cells)[46]. Studies amongst Alaskan indigenous ethnicities (a heterogeneous group of 
Eskimos, Native Indians and Aleuts) reported an incidence of 0.7 cases per million[47]. 
In Australia, Aboriginal and Torres Strait Island children were 1.83 times more likely 
to die from neuroblastoma than nonindigenous children while only contributing 3.7% 
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Table 2 Incidences of neuroblastoma according to the age at diagnosis
Country n < 12 mo < 60 mo Ratio < 12: < 60 < 120 mo < 180 mo Total incidence
South America
Argentina (2000-2012)[29] 753 32.9 14.6 2.3: 1 2.8 1.0 8.3
Uruguay (2001-2010)[35] 69 63.1 18.1 3.4: 1 2.3 0 9.1
Chile (2007-2012)[31] 88 21.9 6.7 3.2: 1 2.1 0.3 4.7
Brazil (1998-2002)[33] 372 15.3 12.4 1.2: 1 3.8 1.3 5.9
Central America and the Caribbean
Mexico (1996-2005)[32] 72 18.5 5.4 3.4: 1 1.1 0.2 3.8
Cuba (2001-2003)[34] 46 3.9 0.8 4.8: 1 0.5 0.2 0.1
Sub-Saharan Africa
Reunion (2005-2011)[36] 12 44.1 15.8 2.7: 1 4.1 0 9.6
of diagnoses[48]. The lower incidence of NB among indigenous ethnicities was not 
reproduced in LMICs of South America or the Pacific Islands[49,50].
Variations in tumour characteristics
Difference in stage during presentation: Many LMICs reported stage 4 rates upward 
of 50%, with India and Pakistan reporting 71.8% and 79% stage 4 tumours respectively 
(Table 4). Egypt, Pakistan and Iran did not report any patients with stage 1 tumours, 
while China and India reported 3% and 1% stage 1 diagnosis respectively[18-20,25]. The 
GFAOP reported metastatic disease for up to 80% of patients except Burkina Faso and 
Morocco, where it varied from 20% to 50%[15]. Kenya reported the highest percentage 
of metastatic disease at 92.3%[44]. The data suggested that presentation in LMIC was 
usually metastatic.
Difference in MYCN amplification: Molecular and genetic diagnostics were not 
available in the greater number of reports and were recorded as a challenge in the 
literature[13,15,51]. In the GFOAP study, only North African countries could determine 
MYCN status[15] with Namibia and South Africa reporting MYCN studies in Southern 
Africa[44]. MYCN is present in about 20% of tumours[51,52]. Limited data are available on 
biological studies, especially genetic studies, in LMICs mainly due to resource 
constraints. In Iran, MYCN amplification was reported in 80% of NB patients, while 
Vietnam, Argentina and Egypt respectively reported rates of 17.8%, 20% and 20.8% 
(Table 4)[14,17,19].
Intra-risk group classification variability: Age groups, biological information and 
treatment protocols were not standardised in the literature, due to the development of 
classifications and changing treatments during the review period. Of note, risk 
classification was either not possible or was done retrospectively. Management 
protocols focus on administering risk-based treatments after identification of the 
classification of each patient yet many patients were treated on the basis of stage[39]. 
LMICs concluded that optimal treatment was doubtful due to the suboptimal 
classification of tumours[9,15,19]. The International Neuroblastoma Risk Group 
classification and the Children’s Oncology Group classification rely on histological and 
genetic information (mitosis-karyorrhexis index, MYCN amplification, 11q aberration 
and DNA ploidy) to determine classification[11], which is not available in many 
resource-limited settings. Even when available, the lack of consistent cytogenetic 
evaluation, as was the case in Argentina, relegated patients in need of high-intensity 
treatment to LR categories and suboptimal treatment[12]. Due to the aggressive nature 
of especially HR NB, palliative rather than curative options have been pursued in 
LMICs[11]. Yet, variability in outcomes has been described within each risk class, 
highlighting that individual assessment is probably suboptimal Therefore, the 
International Society for Paediatric Oncology (SIOP)-Paediatric Oncology for 
Developing Countries (PODC) has adapted the approach to risk stratification with 
therapy based on available resources and utilising available diagnostic techniques[11]. 
The classification relies on age, stage and the common available nonspecific tumour 
markers ferritin and lactate dehydrogenase for risk classification[11]. Morocco has 
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Table 3 Distribution of sex at diagnosis
Country Total Male Female Ratio M: F
Asia
Pakistan (2015-2016)[20] 70 1.8: 1
India (2000-2017)[64] 85 57 (67%) 28 (33%) 2: 1
India (1990-2004)[19] 103 76 (74%) 27 (26%) 2.8: 1
Thailand (2000-2007)[21] 67 39 (58.2%) 23(34.3%) 1.7: 1
Vietnam (2010-2012)[22] 130 76(58.5%) 54 (41.6%) 1.4: 1
China (2008-2013)[17] 59 35 (59%) 24 (40.1%) 1.5: 1
China (2000-2006)[18] 98 1.3: 1
South America
Brazil (1991-2012)[30] 258 148 (57%) 110 (43%) 1.3: 1
Brazil (1990-2000)[16] 125 68 (54.4%) 57 (45.6%) 1.2: 1
Argentina (1999-2015)[12] 39 21 (54%) 18 (46%) 1.2: 1
Argentina (2000-2012)[29] 971 509 (52%) 462 (48%) 1.1: 1
Middle East and North Africa
Iran (1974-2005)[25] 219 1.9: 1
Iraq (2008-2014)[26] 62 37 (59.7%) 25 (40.3%) 1.5: 1
Morocco (2012-2015)[27] 40 26 (65%) 14 (35%) 1.8: 1
Egypt (2005-2010)[23] 142 68 (51.5%) 64 (48.5%) 1.06: 1
Egypt (2001-2010)[24] 53 35 (66%) 18 (35%) 1.9: 1
Egypt (2007-2011)[28] 271 169 (62.4%) 102 (37.6%) 1.65: 1
Sub-Saharan Africa
Northern Nigeria (2003-2009)[80] 14 10 (71.4%) 4 (28.6%) 2.5: 1
Southern Africa (South Africa and Namibia) (1983-1997)[43] 1.7: 1
Ethiopia (2010-2013)[79] 5 3 (60%) 2 (40%) 1.5: 1
Kenya (1997-2005)[44] 22 11 (50%) 11 (50%) 1: 1
implemented this classification system in the prospective NB protocol and has 
concluded that it allowed for more accurate diagnosis and systematic treatment[27]. For 
more accurate comparisons across resource-limited settings, classifications such as the 
SIOP-PODC classification should be standardly applied.
Variable reporting and treatment priorities
Reports from LMICs were predominantly single-institution reports. A multi-
institutional survey by the GFAOP[15] and a review from India including 17 institutions 
and 11 cities[3] described the epidemiology, heterogeneous management approaches 
and outcomes of NB in LMICs[5]. Sub-Saharan African countries reported lower 
incidences of NB (3%-7.5%) among childhood malignancies compared to North-
African countries (7%-30%)[15]. The same study identified the limitations of reporting: 
Plain radiography, ultrasonography, computed tomography and magnetic resonance 
imaging were available at all centres, but access to imaging studies was variable. None 
of the sub-Saharan centres had metaiodobenzylguanidine scans. The North African 
centres had these scans, but only Algeria had consistent access due to government 
funding[15]. In Honduras and the Philippines, diagnostic resources were available in 
large cities but were inaccessible to most patients living in rural areas[50]. This is a 
typical problem in LMICs[53]. An Indian multi-study review concluded that variability 
in India included treatment protocols, reporting of outcomes and calculation of 
survival rates[13]. This conclusion could also be applied to other LMICs. Morocco and 
Argentina were the only LMICs to describe prospective national studies regarding 
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Table 4 Disease characteristics of neuroblastoma at diagnosis
Country n Stage 1 Stage 4 Non-MYCN amplified MYCN amplified Non-HR HR
Asia
China (2008-2013)[17] 59 6.8% 37.3% 55% 45% 53% 47%
China (2000-2006)[18] 98 3% 50%
India (1990-2004)[19] 103 1% 71.8%
Pakistan (2015-2016)[20] 70 0% 79% > 61.1%
South America
Argentina (2000-2012)[29] 753 12% 55.5% 80% 20%
Brazil (1991-2012)[30] 258 15% 46% 75% 25%
Brazil (1990-2000)[16] 125 7% 64% 53% 47%
Middle East and North Africa
Egypt (2005-2010)[23] 142 0% 64.7% 24.2% 75.8%
Egypt (2001-2010)[24] 53 0% 67.9% 79.2% 20.8% 32% 68%
Iran (1974-2005)[25] 219 14.5% 53.8%
Iraq (2008-2014)[26] 62 1.6% 69.4% 45.2% 54.8%
Sub-Saharan Africa
Kenya (1997-2005)[44] 26 0% 92.3%
HR: High-risk.
NB[27,29]. This is representative of the diverse, nonstandardised approach to NB in most 
LMICs. Most studies found a lack of access to biological tests for stratification (based 
on HIC-validated data), the presentation of advanced disease, poor socioeconomic 
circumstances and a significant percentage of patients who absconded from 
treatment[23,24]. Advanced disease and higher than average percentages of HR disease 
were described (Table 4). The PODC committee of the SIOP has developed adapted 
guidelines for the management of NB in LMICs[11]. Yet, in the field of paediatric 
oncology, especially in sub-Saharan Africa, a prioritised, stepwise approach has been 
advised in limited-resource settings, prioritising pain management, supportive care, 
comorbid diseases and malignancies with a higher incidence and relatively 
uncomplicated treatment regimens above rare childhood malignancies[54]. In Africa, 
only Morocco has published data from standardised prospective NB protocols from 
four POUs based on the PODC guidelines[27].
Challenges in improving outcomes
Clinical presentation, index of suspicion and misdiagnosis: Because of its 
heterogeneous clinical presentation, NB can be challenging to diagnose[30]. The 
presenting signs of NB can be similar to those of non-malignant diseases and can 
confound recognition of the disease[10,55]. Symptoms of an NB abdominal mass can be 
misdiagnosed as more common childhood illnesses such as constipation[56]. In LMICs, 
similar to HICs, the most common presentation reported in 19%-87% of patients was 
an abdominal mass (Table 5)[18,19,23,30]. Other common presentations were nonspecific 
abdominal pain (22%-73.5%)[18,30] and fever (25%-65%)[18,19,23,30], metastatic manifestations 
such as bilateral proptosis (27%-42.4%)[19,23], bone pain (19%)[30] and pancytopaenia, and 
constitutional symptoms such as loss of weight[56]. The clinical progression of the 
tumour involves a spectrum of behaviour from aggressive advancement to metastatic 
disease or spontaneous regression and mature differentiation of cell types such as 
ganglioneuroma[29,57]. Health care practitioners must have a high index of suspicion for 
NB with a varied clinical picture[35]. Misdiagnosing NB from other abdominal tumours 
prevents accurate registration of the diagnosis[29]. In resource-limited settings, the 
diagnosis of asymptomatic benign clinical types is less common, possibly due to 
underdiagnosis. Early detection by screening in HICs neither impacted outcomes nor 
was it cost-effective[57]. While the incidence was increased during active screening of 
the disease in the European, North American and Japanese context, surgical 
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Table 5 Most common clinical presentations in low- and middle-income countries
Asia
China (2000-2006)[18] Abd pain (73.5%) Abd mass (54.1%) Fever (45.9%) Limb pain (25.5%)
India (1990-2004)[19] Fever (65%) Abd mass (54%) Bone pain (31%) Proptosis (27%)
South America
Brazil (1991-2012)[30] Fever (25%) Abd pain (22%) Abd mass (19%) Bone pain (19%)
Middle East and North Africa
Egypt (2005-2010)[23] Abd mass (87%) Pallor (57.6%) Fever (45.5%) Proptosis (42.4%)
Sub-Saharan Africa
Kenya (1997-2005)[44] Abd mass (53.8%) Bone pain (50%) Proptosis (38.5%) Fever (19.8%)
interventions were increased without improvement of survival[57].
Access to and assignment of treatment: The number and capacities of POUs varied 
substantially among LMICs, and capacities also varied among POUs in a single 
country[50]. Basic paediatric oncology components were not available in the Philippines 
and Senegal[50], while Venezuela and Egypt had adequate intensive care facilities and 
even transplant services[50]. This is also true of POUs in South Africa[44]. Furthermore, 
paediatric services may not even exist in certain countries or often compete with adult 
services for resources[54].
Current treatment protocols are based on risk stratification[11]. The LMIC reports 
included treatments over four decades[13,30]. Therefore, outcomes were predominantly 
reported per stage and, subsequently, as classification systems evolved, research 
describing the treatment of LR and intermediate-risk (IR) patients but focussing 
primarily on HR disease as the greatest NB burden was reported.
In many LMICs, NB treatment choices are limited to mainly chemotherapy, surgery 
and radiotherapy[1]. In HR NB, multimodal therapy is of vital importance for cure and 
five-year OS of up to 60% (Figure 1).
Due to advanced disease at diagnosis, palliative treatment is often the only plausible 
option (Figure 1). Other challenges for the management of NB include lack of surgical 
and radiotherapy skills or equipment as well as lack of chemotherapy[1,11]. Poor 
outcomes have necessitated the development of palliative strategies, yet many LMICs 
where drug insecurity is high do not have even basic medicines for palliation[58]. 
Resources, drug security and expertise in institutions influence treatment decisions to 
a similar extent as treatment adherence and response to treatment. The ability of 
facilities to provide supportive care, in terms of antibiotics, intensive care and 
granulocyte-stimulating factors, influences decision making regarding the intensity of 
treatment that patients receive[10,11].
Treatment protocols utilised in low- and medium-income countries and outcomes: 
Over the past decades, guidelines for the treatment of NB have changed as a result of 
an improved understanding of biological prognostic factors and changing 
classification systems yet chemotherapy remains based on etoposide and platinum 
(cisplatin and/or carboplatin) backbones plus dose- and time-intensive administration 
of chemotherapy[11]. Some approaches include doxorubicin in the regimens, while the 
SIOP-PODC treatment guidelines for NB are based on settings relating to the level of 
supportive care and resources available in a POU[11]. Indicators for reporting outcomes 
were not consistent over the same period. Some studies reported according to stage, 
while others reported according to risk classification.
The GFAOP administered various local and international protocols based on the 
standard backbone including doxorubicin[15]. Individual POUs reported a long-term 
OS of less than 10% for metastatic disease. Tunisia reported an OS of 78% for non-
metastatic disease, while Senegal reported an OS (metastatic plus non-metastatic) of 
38.9%. The report concluded that with all countries having access to surgical options, 
the outcomes were ‘generally poor’ and standardised protocols were being developed 
for multicentre use[15]. In Morocco, a GFAOP member, a national prospective protocol 
divided into an HR protocol and a non-HR protocol based on the risk-adapted SIOP-
PODC treatment guidelines was studied[11,15,27]. Long-term outcomes were not reported, 
but 60.6% of HR patients experienced a partial or very good partial response, receiving 
local control with surgery or consolidation therapy[27]. The study concluded that risk 
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Figure 1  Challenges of non-tumour-related factors during the treatment of high-risk neuroblastoma in low- and middle-income countries. 
ASCT: Autologous stem-cell transplant; HIC: High-income country; CRA: Cis-retinoic acid.
stratification and treatment guidelines adapted for LMICs improved the accuracy of 
diagnosis and access to systematic treatment[27]. The protocol was also suitable for 
multicentre use[27].
A Chinese study administered OPEC by modifying the Japanese study group 
protocol[18]. The five-year OS was 80% for stages 1 and 2 and 48.3% and 20% for stages 
3 and 4 respectively, which was less than the Japanese outcomes[18].
Egyptian and Indian centres based their HR treatment on the North American CCG-
3891 protocols, while other LMIC centres administered chemotherapy according the 
European protocols from France and the International Society of Paediatric Oncology 
European Neuroblastoma Research Network (SIOPEN)[59]. Indian institutions followed 
a non-standardised approach including OPEC/OJEC, doxorubicin-containing and 
Ifosfamide-containing regimens[13]. Iran and Egypt used OPEC/OJEC regimens[23-25], 
while Brazil, Thailand and China followed doxorubicin-based regimens[16-18,21,30]. Stage 1 
disease had a five-year OS of 100% in Brazil[16], China[17,18] and Thailand[21], while stage 4 
OS was under 20%[16,18]. The three-year OS for stage 4 disease in Thailand and China 
was less than 35%[17,21]. While the outcomes for stage 1 disease were comparable to 
HICs, the poorer stage 4 outcomes were less optimal than in HICs[10]. The same 
conclusion was reached in an Indian study with three-year OS and event-free survival 
for non-metastatic disease of 77% and 54% respectively[60].
Argentina alternated between rapid COJEC and the modified N7 for HR disease 
according to the SIOPEN HR NBL-1 protocol[12]. The five-year OS was 24%. The study 
concluded that improved supportive care, optimal treatment and maximising 
available resources were needed[12]. A second Argentinian study associated lower 
socioeconomic status with poorer outcomes independent of treatment[29].
In LMICs, no conformity was found in the management of NB amongst regions 
within countries. Failing to complete one aspect of the sequential treatment protocol 
relegates the outcome to being suboptimal. This is often the case in LMICs with 
limited access to health care and limited resources for optimal treatment[61]. It is 
possible that without genetic factors to distinguish more clearly between IR and HR 
disease, the IR cohorts in LMICs contain a number of HR patients, thereby affecting 
outcomes[11].
Main factors affecting outcomes: LMICs have identified treatment-related, tumour-
related and social factors that affect the outcomes of children with NB. Delayed 
diagnosis[30] and inaccurate diagnosis of tumours due to limited radiologic and 
pathology resources were cited as major obstacles[25,27,60]. The limited ability to perform 
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biological testing impaired accurate risk stratification[25,27,30,62]. Centres with higher 
levels of supportive care reported the inability to perform bone marrow transplants as 
a limitation to improving outcomes[24,60]. The variability of tumours and nonspecific 
presentation contributed to late diagnosis and the incidence of advanced 
disease[12,25,27,30,62]. Yet, the greatest problems were the abandonment of treatment and 
patients lost to follow-up of up to 50%[11,70,62], which were linked to social factors and 
the distance from treatment centres[12].
Social circumstances and outcomes: A Brazilian study reported intraregional 
variation in the incidence of NB based on socioeconomic status[33]. The study 
concluded that patients from regions with a lower socioeconomic status had poorer 
outcomes[33]. In South African populations, socioeconomic and/or cultural factors 
related to access to or utilisation of health care services are a possible contributing 
factor to poorer outcomes[1]. A large proportion of rural inhabitants have restricted 
access to medical facilities and thus experience a delay in treatment[1,63,64]. A Harvard 
study concluded that in the United States of America, NB diagnosis was influenced by 
social circumstances[65]. According to the study, the Human Development Index 
showed a direct relationship between socioeconomic status and the incidence of NB[65].
Factors influencing health-seeking behaviour: The heterogeneous and aggressive 
pathophysiology of NB demands prompt response and immediate medical 
intervention for nonspecific symptoms[66,67]. The economic structure of LMICs 
influences the affordability of healthcare and parental education[68-70]. These factors 
determine the promptness of the response to and the action taken with regard to 
nonspecific symptoms associated with the initial phases of childhood malignancies. 
The steadfast belief in traditional medicine as a first treatment option and cultural 
systems in which elders or a single authority figure decide about seeking medical 
intervention may delay action towards directed care[71,72]. Political stability and 
government policies have a direct impact on the availability, accessibility and quality 
of health care systems in treating childhood cancer[73,74].
Research priorities
The focus of research for LMICs should be on creating greater awareness in the 
diagnosis of NB, improving diagnostics and establishing social support strategies for 
successful, harmonised management protocols and homogenous treatment facilities to 
improve outcomes[55,75]. The main priority should be accurate tumour registries to 
document not only the most common or treatable childhood malignancies but also the 
rarer tumours such as NB[37]. In resource-limited settings, the need for genetic markers 
to develop more accurate risk classifications exists, especially to distinguish clearly 
between IR and HR patients. This is important in the case of stage 2 and stage 4 
patients with adverse biology tumours who have in a higher risk classification 
compared to patients with non-adverse biology tumours[11,25,29]. Genome and exome 
sequencing have improved the understanding of the pathophysiology of NB in 
HICs[76]. However, knowledge regarding genetics of NB in the diverse ethnicities in 
LMICs is limited. A further challenge would be to make treatments and advanced 
diagnostics, such as liquid biopsies and biological tests, more widely available to all 
countries, whether HICs or LMICs, to improve diagnostic capacities and outcomes[75]. 
In advanced disease, palliative research could contribute to a greater understanding of 
the role of metronomic therapies and disease control in the context of NB[77].
DISCUSSION
Childhood malignancy awareness and advocacy still face great challenges, especially 
in LMICs, notably countries with large rural populations and great geographical 
divides, in accurately diagnosing malignancies, especially heterogeneous tumours 
such as NB. The lack of uniform treatment protocols for this variable disease is still a 
barrier to care. Epidemiological data are reproducible in different international 
studies, but data from across the world are not uniform. More research regarding 
tumour biology, specifically genomics, is needed not only in HICs but also in LMICs to 
determine underlying differences in molecular biology of the tumours, genetic targets 
and drug processing of NB patients, especially in heterogeneous populations. This 
information must then be made available to treatment centres where biological 
investigation is not possible, ready for clinical application to achieve improved 
outcomes for NB worldwide.
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ARTICLE HIGHLIGHTS
Research background
Neuroblastoma (NB) is a well-documented childhood malignancy with the greatest 
source of knowledge originating from high-income countries. The management of NB 
in low- and middle countries (LMIC) is less robust due to various social and resource 
limitations.
Research motivation
The outcomes of various LMIC during the same period like South America, 
Francophone/North African countries, Asia and South Pacific Islands was evaluated.
Research objectives
This literature review was to evaluate regional development of management protocols, 
the challenges in treating NB in paediatric oncology units in LMIC as compared to 
high-income countries, new laboratory and clinical developments in the treatment of 
NB.
Research methods
A literature review of publications searched on PubMed, Medline, Global Health, 
Embase, SciELO and Google Scholar with keywords in keeping with NB and 
outcomes. Due to the variability in reporting, nonstandard application of definitions in 
the reported clinical results, heterogeneous data and paucity of information, the 
authors constructed limited tables to evaluate clinical and/or biological characteristics 
to report in the descriptive review.
Research results
Childhood malignancy awareness and advocacy still face great challenges, especially 
in LMICs, in accurately diagnosing malignancies, especially heterogeneous tumours 
such as NB. The lack of uniform treatment protocols for this variable disease is still a 
barrier to care. Epidemiological data are reproducible in different international 
studies, but data from across the world are not uniform.
Research conclusions
More research regarding tumour biology, specifically genomics, is needed not only in 
high-income countries but also in LMICs to determine underlying differences in 
molecular biology of the tumours, genetic targets and drug processing of NB patients, 
especially in heterogeneous populations.
Research perspectives
The focus of research for LMICs should be on creating greater awareness in the 
diagnosis of NB, improving diagnostics and establishing social support strategies for 
successful, harmonised management protocols and homogenous treatment facilities to 
improve outcomes. In resource-limited settings, the need for genetic markers to 
develop more accurate risk classifications exists. A further challenge would be to make 
treatments and advanced diagnostics, such as liquid biopsies and biological tests, more 
widely available to all countries. With advanced disease, palliative research could 
contribute to a greater understanding of the role of metronomic therapies and disease 
control in the context of NB.
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